News & Events about Allovir Inc.
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the companys 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates...
Business Wire
2 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic cell...
Business Wire
7 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK...
Ticker Report
9 months ago
Shares of AlloVir, Inc. (NASDAQ:ALVR Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $5.41, but opened at $7.29. AlloVir shares last traded at $8.25, with a volume of 885,061 shares trading hands. Several equities analysts recently issued ...
Thinking about buying stock in Allovir, Sono Group, Ion Geophysical, Toughbuilt, or Snowflake? Thinking about buying stock in Allovir, Sono Group, Ion Geophysical, Toughbuilt, or Snowflake? PR Newswire NEW YORK, April 20, 2022 NEW YORK, April 20, 2022 /PRNewswire/ -- InvestorsObserver issues...